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A B S T R A C T
Background
Tumour lysis syndrome (TLS) is a serious complication of malignancies and can result in renal failure or death. Preliminary reports
suggest that urate oxidase is effective in reducing serum uric acid, the build-up of which causes TLS. It is uncertain whether high-
quality evidence exists to support its routine use in children with malignancies.
Objectives
To assess the effects and safety of urate oxidase for the prevention and treatment of TLS in children with malignancies.
Search methods
This is an update of the original review. We performed a comprehensive search of the Cochrane Central Register of Controlled Trials
(CENTRAL) (in The Cochrane Library issue 1, 2013), MEDLINE (1966 to February 2013), Embase (1980 to February 2013), and
CINAHL (1982 to February 2013). In addition, we searched the reference lists of all identified relevant papers. We also explored other
internet sources (updated search on 26 February 2013): the NHS’ National Research Register, the US National Institutes of Health
Ongoing Trials Register, the metaRegister of Controlled Trials, and ProQuest Dissertations & Theses Database. We also screened
conference proceedings of the American Society of ClinicalOncology, the European Society forMedicalOncology, and the International
Society of Paediatric Oncology meetings from 1993 to 2012. Finally, we contacted experts in the field and the manufacturer of
rasburicase, Sanofi-aventis.
Selection criteria
Randomised controlled trials (RCT) and controlled clinical trials (CCT) of urate oxidase for the prevention or treatment of TLS in
children under 18 years with any malignancy.
Data collection and analysis
Two review authors independently extracted trial data and assessed individual trial quality. We used risk ratios (RR) for dichotomous
data and mean difference (MD) for continuous data.
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Main results
We included seven trials, involving 471 participants in the treatment groups and 603 participants in the control groups. One RCT and
five CCTs compared urate oxidase and allopurinol. Three trials tested Uricozyme, and three trials tested rasburicase for the prevention
of TLS.
The RCT showed no significant difference in mortality (both all-cause mortality and mortality due to TLS), renal failure, and adverse
effects between the treatment and the control groups. The frequency of normalisation of uric acid at four hours (Fisher’s exact test
P < 0.001) and area under curve of uric acid at four days (MD -201.00 mg/dLhr, 95% confidence interval (CI) -258.05 mg/dLhr
to -143.95 mg/dLhr; P < 0.00001) were significantly better in the treatment group. The trial did not evaluate the primary outcome
(incidence of clinical TLS).
Pooled results of three CCTs showed significantly lower mortality due to TLS in the treatment group (RR 0.05, 95% CI 0.00 to 0.89; P
= 0.04); all-cause mortality was not significantly different between the groups. Pooled results from five CCTs showed significantly lower
incidence of renal failure in the treatment group (RR 0.26, 95% CI 0.08 to 0.89; P = 0.03). Results of CCTs also showed significantly
lower uric acid in the treatment group at two days (three CCTs), three days (two CCTs), four days (two CCTs), and seven days (one
CCT) after therapy, but not one day (three CCTs), five days (one CCT), and 12 days (one CCT) after therapy. Pooled results from
three CCTs showed higher frequency of adverse effects in participants who received urate oxidase (RR 9.10, 95% CI 1.29 to 64.00; P
= 0.03). One CCT evaluated the primary outcome; no significant difference was identified.
Another included RCT, with 30 participants, compared different doses of rasburicase (0.2 mg/kg versus 0.15 mg/kg), which demon-
strated no significant difference in uric acid normalisation and uric acid level at four hours). Common adverse events of urate oxidase
included hypersensitivity, haemolysis, and anaemia, but no significant difference between treatment groups was identified. No signifi-
cant difference in mortality (all-cause mortality and mortality due to TLS) and renal failure was identified. The primary outcome was
not evaluated.
All included trials were highly susceptible to biases.
Authors’ conclusions
Although urate oxidase might be effective in reducing serum uric acid, it is unclear whether it reduces clinical tumour lysis syndrome,
renal failure, or mortality. Adverse effects might be more common for urate oxidase compared with allopurinol. Clinicians should
weigh the potential benefits of reducing uric acid and uncertain benefits of preventing mortality or renal failure from TLS against the
potential risk of adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Urate oxidase for the prevention and treatment of complications from massive lysis (breakdown) of tumour cells in children
with cancer
Tumour lysis syndrome occurs when uric acid and other cellular substances are rapidly released into the circulation when tumour cells
are broken down spontaneously or during treatment. Uric acid has low solubility (does not dissolve easily); therefore, it can build up
in the kidney resulting in kidney failure and possibly death eventually. Urate oxidase is an enzyme that can be administered to patients
at risk of tumour lysis syndrome to convert uric acid to a more soluble product, allantoin, which can be excreted by the kidneys more
readily. Therefore, urate oxidase may be able to prevent or treat tumour lysis syndrome in patients with malignancies. However, the
current systematic review of (randomised) controlled clinical trials found that although urate oxidase might be effective in reducing
serum uric acid level, it has not been confirmed to reduce renal failure or mortality from tumour lysis syndrome in children with cancer.
Adverse effects might be more common in patients who receive urate oxidase compared with allopurinol. Urate oxidase needs to be
further evaluated, especially in high-risk patients, such as those with high-risk leukaemia and lymphoma.
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B A C K G R O U N D
Tumour lysis syndrome (TLS) is a serious complication of malig-
nancies that can occur spontaneously in the presence of rapidly
proliferating tumour cells or during treatment because of rapid cell
lysis, leading to release of intracellular components that may result
in hyperkalaemia, hyperphosphataemia, hypocalcaemia, or hype-
ruricaemia. Hyperuricaemia and hyperphosphataemia can result
in crystallisation in the renal tubules causing obstructive uropathy
and renal failure. Other severe consequences of tumour lysis syn-
drome include cardiac arrhythmia and sudden death from hyper-
kalaemia (Navolanic 2003; Rampello 2006). The Cairo-Bishop
definition for laboratory tumour lysis syndrome is the develop-
ment of any two or more of the following four criteria within three
days before or seven days after the initiation of chemotherapy: uric
acid level ≥ 8 mg/dL, potassium level ≥ 6 mmol/L, phosphate
level ≥ 6.65 mg/dL, and calcium level ≤ 7 mg/dL. A 25% in-
crease from baseline for uric acid, potassium, or phosphate levels
or a 25% decrease from baseline for calcium level is an alternative
threshold (Cairo 2004). The Cairo-Bishop definition for clinical
tumour lysis syndrome is the presence of laboratory tumour lysis
syndrome and one or more of the following three criteria: serum
creatinine level ≥ 1.5 times the upper limit of normal, cardiac
arrhythmias, sudden death, or seizures.
Risk factors for tumour lysis syndrome include high proliferation
rate, large tumour burden, andhigh chemosensitivity. A highwhite
blood cell count in leukaemia (> 50 x 10 /L) or a high lactate
dehydrogenase level in lymphoma indicates high tumour burden.
Certain malignancies, such as Burkitt’s lymphoma, are associated
with a very high risk of tumour lysis syndrome because of rapid
tumour cell turnover (Wössmann 2003). The incidence of tu-
mour lysis syndrome varies among studies. A retrospective review
of acute lymphoblastic leukaemia, acute myeloid leukaemia, and
non-Hodgkin’s lymphoma found that the frequency of tumour
lysis syndrome was 3.4%, 5.2%, and 6.1%, respectively, and it ac-
counts for 0.9% of cancer mortality (Annemans 2003a). Themor-
tality rate of tumour lysis syndrome has been estimated to be about
17.5% (Annemans 2003a). The medical costs of hyperuricaemia
and tumour lysis syndrome are substantial. The cost of hyperuri-
caemia without tumour lysis syndrome has been estimated to be
EURO672, and the cost of tumour lysis syndrome, EURO7342
(Annemans 2003a). The cost of tumour lysis syndrome requiring
dialysis has been shown to be even higher (EURO17,706 on av-
erage) (Annemans 2003a).
Aggressive hydration and allopurinol, with or without urinary al-
kalinisation with bicarbonate, is the standard prophylaxis for tu-
mour lysis syndrome. Allopurinol is a xanthine oxidase inhibitor,
which prevents the formation of uric acid but does not catabolise
(so degrade and detoxify) existing uric acid. Allopurinol is there-
fore not an effective treatment for established tumour lysis syn-
drome since it does not promote uric acid clearance. Because of
the inhibition of xanthine oxidase, allopurinol increases the level
of uric acid precursors, hypoxanthine and xanthine. As xanthine
is less soluble than uric acid, it may precipitate in renal tubules
causing xanthine nephropathy (kidney disease) or xanthine stones
(Greene 1969).
Urate oxidase is an alternative agent used for the treatment or pro-
phylaxis of hyperuricaemia in patients who are at high risk of tu-
mour lysis syndrome. Urate oxidase converts uric acid to allantoin,
which is five to 10 times more soluble than uric acid and readily
excreted in urine. A non-recombinant form of urate oxidase has
been available in Europe for more than 20 years, but it is associ-
ated with acute hypersensitivity reactions in 4.5% of patients (Yim
2003). Rasburicase, a relatively new, recombinant urate oxidase
enzyme produced by a genetically modified Saccharomyces cere-
visiae strain, has now replaced the older agent and is widely used.
Reported advantages of urate oxidase over allopurinol include its
ability to catabolise existing uric acid in established tumour lysis
syndrome; no increased risk of xanthine stone formation; no re-
quirement for dose adjustment in acute renal failure; lack of clin-
ically relevant drug-drug interaction; and lower incidence of ad-
verse reactions, such as skin rash, fever, eosinophilia, and Stevens
Johnson syndrome (Gutierrez 2005; Sanofi 2011). Anecdotal re-
ports and case series have indicated that urate oxidase may be ef-
fective in the prevention and treatment of tumour lysis syndrome
(Bosly 2003; Coiffier 2003; Hummel 2003; Hutcherson 2006;
Jeha 2005; Lascombes 1998; Lee 2003; Liu 2005; McDonnell
2006; Pui 2001a; Pui 2001b; Shin 2006; Trifilio 2006; Wang
2006), resulting in a significant reduction of serum uric acid level
and a low incidence of renal failure requiring dialysis. In addition,
the use of urate oxidase has been reported to be cost-effective for
the prevention and treatment of tumour lysis syndrome in both
children and adults (Annemans 2003b). However, it is not en-
tirely certain whether the existing evidence is sufficiently rigor-
ous to support the routine use of urate oxidase as prophylaxis in
children with malignancies at risk of tumour lysis syndrome, or
as a treatment for established laboratory or clinical tumour lysis
syndrome. It is also uncertain whether single or multiple doses of
urate oxidase should be used or which types of high-risk patients
benefit most from prophylactic administration of urate oxidase.
Although there are consensus guidelines developed for the man-
agement of tumour lysis syndrome (Coiffier 2008; Tosi 2008),
they did not include the latest evidence from systematic review.
Therefore, we examined the efficacy and safety of urate oxidase in
children with malignancies in a systematic review of randomised
controlled trials and controlled clinical trials (Cheuk 2010). This
is an update of that systematic review.
O B J E C T I V E S
To assess the effects and safety of urate oxidase for the prevention
and treatment of TLS in children with malignancies.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in the review.
We also planned to include controlled clinical trials (CCTs) if no
(or few) RCTs were available. A CCT is a study that compares one
or more intervention groups to one or more control groups. We
included historical controlled studies.
Types of participants
We included participants under 18 years of age with all types of
cancer, including haematological malignancies and solid tumours.
Types of interventions
We included trials evaluating all preparations of urate oxidase. The
control interventions could be placebo; no treatment; or other
treatment, such as allopurinol. We also included trials comparing
urate oxidase combinedwith other treatment versus the same other
treatment alone, and trials comparing different doses or different
preparations of urate oxidase.
Types of outcome measures
For evaluation of urate oxidase as prevention for tumour lysis
syndrome, we assessed the following outcome measures.
Primary outcome
1. Incidence of clinical tumour lysis syndrome according to
Cairo-Bishop definition.
Secondary outcomes
1. Incidence of laboratory tumour lysis syndrome according to
Cairo-Bishop definition.
2. Mortality associated with tumour lysis syndrome and
combined with other reasons.
3. Incidence of renal failure requiring renal replacement
therapy associated with tumour lysis syndrome.
4. Frequency of normalisation of serum uric acid level.
5. Duration before normalisation of serum uric acid level.
6. Change in serum uric acid level.
7. Area under curve (AUC) of uric acid level.
8. Frequency of adverse effects.
For the evaluation of urate oxidase as treatment for tumour lysis
syndrome, we assessed the following outcome measures.
Primary outcome
1. Mortality associated with tumour lysis syndrome and
combined with other reasons.
Secondary outcomes
1. Incidence of renal failure requiring renal replacement
therapy associated with tumour lysis syndrome.
2. Frequency of normalisation of serum uric acid level.
3. Duration before normalisation of serum uric acid level.
4. Change in serum uric acid level.
5. Area under curve (AUC) of uric acid level.
6. Change in serum phosphate level.
7. Change in serum potassium level.
8. Change in serum creatinine level.
9. Change in serum calcium level.
10. Frequency of adverse effects.
Search methods for identification of studies
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (issue 2, 2009 for the origi-
nal review, and issue 1, 2013 for the update),MEDLINE/PubMed
(1966 to August 2009 for the original review, and to February
2013 for the update), Embase (1980 to August 2009 for the orig-
inal review, and to February 2013 for the update), and CINAHL
(Cumulative Index toNursing andAlliedHealth Literature) (1982
to August 2009 for the original review, and to February 2013 for
the update).
The search strategies used for the different electronic databases (us-
ing a combination of controlled vocabulary and text word terms)
are shown in the Appendices (Appendix 1; Appendix 2; Appendix
3; Appendix 4).
We searched the reference lists of all identified relevant papers for
further studies. We also explored other internet sources (updated
search on 28 February 2013):
• the NHS’ National Research Register (for the original
review: www.update-software.com; for the update:
www.nihr.ac.uk/Pages/NRRArchiveSearch.aspx);
• the US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov);
• metaRegister of Controlled Trials (www.controlled-
trials.com/mrct); and
• ProQuest Dissertations & Theses Database (for the original
review: wwwlib.umi.com/dissertations; for the update:
search.proquest.com).
We also handsearched abstracts from the meetings of the ASCO
(American Society of Clinical Oncology), ESMO (European So-
ciety for Medical Oncology), and SIOP (International Society of
Paediatric Oncology) from 1993 to 2009 for the original review,
and 2010 to 2012 for the update.
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We also included articles published only in abstract form if we
could contact the authors to provide essential details for appraisal
and analysis. If the process of searching many different sources
brought to light direct or indirect references to unpublished stud-
ies, we planned to obtain copies of such unpublished material.
In addition, we contacted colleagues and experts in the field to
ascertain any unpublished or ongoing studies. We also contacted
the manufacturer of rasburicase, Sanofi-aventis, for published and
unpublished clinical studies.
There was no language restriction in the search and inclusion of
studies. However, we excludedmultiple publications reporting the
same group of participants or its subsets.
Data collection and analysis
Selection of studies
Two authors (the first and second authors) independently reviewed
titles and abstracts of references retrieved from the searches and
selected all potentially relevant studies. The same authors obtained
copies of these articles and reviewed them independently against
the above-mentioned inclusion and exclusion criteria for study se-
lection. Authors were not blinded to the names of the trial authors,
institutions, or journal of publication. We planned for the third
author to resolve any discrepancies regarding selection of studies if
necessary, but there was no discrepancy and the third author was
not called upon.
Data extraction and management
Two authors extracted data from included trials, independently.
We planned for the third author to resolve any discrepancies re-
garding data extraction if necessary, but there was no discrepancy
and the third author was not called upon.
We extracted the following data.
1. Study methods
i) design (i.e. RCT or CCT)
ii) randomisation method (including list generation)
iii) method of allocation concealment
iv) blinding method
v) stratification factors
2. Participants
i) inclusion/exclusion criteria
ii) number of participants entering the trial, number of
participants randomised, number of excluded participants (with
reasons), and number of evaluable participants
iii) age and gender distribution
iv) type of malignancies
v) treatments for the malignancies (chemotherapy,
radiotherapy, autologous stem cell transplant, allogeneic stem
cell transplant)
vi) baseline renal function, uric acid level, potassium level,
phosphate level, calcium level, lactate dehydrogenase (LDH)
level, white blood cell (WBC) counts (for leukaemia), rate of
decrease of WBC (for leukaemia), and sizes of the liver and spleen
3. Intervention and control
i) type of uric oxidase
ii) type of control treatment
iii) details of administration of urate oxidase, including
dosage and schedules
iv) details of co-interventions
4. Follow-up data
i) duration of follow-up
ii) loss to follow up
5. Outcome data
i) serial uric acid levels measurement
ii) days to normalisation of uric acid level
iii) number of criteria of laboratory tumour lysis
syndrome according to Cairo-Bishop definition
iv) number of criteria of clinical tumour lysis syndrome
according to Cairo-Bishop definition
v) change in serum potassium, calcium, phosphorus, and
creatinine levels
vi) adverse effects
6. Analysis data
i) methods of analysis (intention-to-treat or per-protocol
analysis)
ii) comparability of groups at baseline (yes/no);
iii) statistical methods
One author entered the data into Review Manager (RevMan) (
RevMan 2013); the other authors then checked the data.
Assessment of risk of bias in included studies
Two authors (the first and second authors) independently assessed
the methodological quality of each eligible trial. We planned for
the third author to resolve any discrepancies regarding risk of bias
assessment if necessary, but there was no discrepancy and the third
author was not called upon.Where necessary, we sought additional
information from the principal investigator of the trial concerned.
We included the following items to assess themethodological qual-
ity of RCTs in the update of the review, according to the latest
recommendation in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011):
• random sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective reporting (reporting bias); and
• other bias.
Similarly, we assessed controlled clinical trials for the above-men-
tioned types of biases; we expected them not to incorporate ran-
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dom allocation of treatment groups or perform allocation conceal-
ment. Because of non-random treatment group allocation, they
were also susceptible to confounding, and we examined possible
confounding factors, including age of the participant, types of
malignancies, baseline renal function, white blood cell (WBC)
counts, lactate dehydrogenase (LDH) level, uric acid levels, and
intensity of chemotherapy.
Measures of treatment effect
We used risk ratio (RR) estimations with 95% confidence inter-
vals (CI) for dichotomous outcomes. We did not calculate a RR if
there was only one study available for a particular outcome, and
there was no event in one of the groups. We used the Fisher’s exact
test (performed using SPSS version 19 (SPSS 2010)) to determine
the P value in such situations. We used mean difference (MD) es-
timations with 95% CI for continuous outcomes. We analysed all
participants in the treatment groups to which they were allocated
(intention-to-treat (ITT) analyses) if there were no missing data;
we planned to performper-protocol analyses if information for in-
tention-to-treat analyses was lacking. We did not impute missing
data. We planned to consider cost-effectiveness of interventions if
relevant data were available.
Dealing with missing data
We contacted the authors of included studies to ask them to supply
missing data. We assessed missing data and dropouts/attrition for
each included study and assessed and discussed the extent to which
the missing data could alter the results/conclusions of the review.
If, for a particular outcome, less than 70% of participants allocated
to the treatments were reported on at the end of the trial, we
reported those data, but considered them prone to bias.
Assessment of reporting biases
We planned to generate a funnel plot (effect size against standard
error) if we found sufficient studies (more than five). Asymmetry
could be due to publication bias, but could also be due to a re-
lationship between trial size and effect size. In the event that we
found a relationship, we planned to examine clinical diversity of
the studies (Egger 1997). However, there were not enough studies
available to prepare a reliable funnel plot.
Data synthesis
Where the interventions were the same or similar enough, we
synthesised results in a meta-analysis if there was no important
clinical heterogeneity. If no significant statistical heterogeneity was
present, we synthesised the data using a fixed-effect model. If there
was unexplained heterogeneity, we used a random-effects model
in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
If data permitted, we conducted subgroup analyses for the follow-
ing:
1. different types of malignancies (acute leukaemia,
lymphoma, solid tumour);
2. different number of doses of urate oxidase (single dose, two
doses, three or more doses); and
3. different levels of risk of tumour lysis syndrome
(participants with rapid cell turnover, high lactate dehydrogenase
(LDH), or baseline hyperuricaemia).
If two or more included trials reported the same outcomes for
the same subgroups, we combined their results in meta-analyses
if no significant heterogeneity was present. We assessed clinical
heterogeneity by comparing the distribution of important partic-
ipant factors between trials (age, type of malignancies) and trial
factors (randomisation concealment, blinding of outcome assess-
ment, losses to follow up, treatment regimens). We assessed statis-
tical heterogeneity of RCTs by examining the I² statistic (Higgins
2002), a quantity that describes approximately the proportion of
variation in point estimates that is due to heterogeneity rather than
sampling error. If significant heterogeneity was present (i.e. I² ≥
50% (Higgins 2011), we explored the trials to investigate possible
explanations.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the impact of
study quality, including the following:
1. all studies; and
2. only those studies with adequate allocation concealment.
We also planned to conduct sensitivity analyses to assess the impact
of heterogeneity, by excluding those with outlying results.
R E S U L T S
Description of studies
Results of the search
In August 2009, the electronic searches retrieved 68 articles from
MEDLINE. We excluded 64 based on title or abstract, because of
obvious irrelevance.We examined the full texts of the four remain-
ing articles. Two were randomised controlled trials (RCTs) satis-
fying the inclusion criteria (Goldman 2001; Kikuchi 2009), and
the other two were controlled clinical trials (CCTs) (Renyi 2007;
Wossmann 2003). We included these two CCTs in the review be-
cause we only identified two RCTs. We also retrieved 100 articles
from Embase. We excluded all but two articles after examining
the title and abstract. The MEDLINE search also identified these
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two articles (Kikuchi 2009; Renyi 2007). We retrieved 17 articles
from the Cochrane Central Register of Controlled Trials (CEN-
TRAL) in The Cochrane Library. We excluded 16 based on title or
abstract, and we included one. This was one of the RCTs identified
in MEDLINE (Goldman 2001). We retrieved 40 articles from
CINAHL, excluding 37 based on title or abstract. The remaining
three articles were the same as those identified and included from
MEDLINE (Goldman 2001; Renyi 2007;Wossmann 2003).We
identified and included one more CCT (Patte 2002) after check-
ing the reference lists of the other included studies. We identified
no additional completed or ongoing trials after checking internet
sources and conference proceedings and contacting experts. There
was no discrepancy in the independent selection of included stud-
ies among the two authors, and a third author was not necessary
in this process.
With the updated electronic search strategy in February 2013,
we retrieved 16 articles from CENTRAL, 53 articles from MED-
LINE/PubMed, 18 articles from Embase, and no article from
CINAHL. We found five studies from checking references of in-
cluded studies and two studies from the US National Institutes of
Health Ongoing Trials Register. We identified no studies by scan-
ning the conference proceedings and contacting experts. In sum-
mary, we found a total of 94 studies in the update search in Febru-
ary 2013. After we removed duplicates, we screened 81 articles for
eligibility. We excluded 69 articles based on title or abstract. We
obtained the full text of the remaining 12 articles. We included
seven studies in this review, including the five studies included in
the original search (Goldman 2001; Kikuchi 2009; Patte 2002;
Rényi 2007; Wössmann 2003) and two additional studies in the
update (Sánchez Tatay 2010; Pui 1997). Two studies were ongo-
ing (see the ’Characteristics of ongoing studies’ tables) and did
not have results available, and we excluded three studies (see the
’Characteristics of excluded studies’ tables). There was no discrep-
ancy in the independent selection of included studies among the
two authors, and a third author was not necessary in this process.
In summary (see Figure 1), we included seven studies (five identi-
fied in the original review and two in the update). Among the seven
included studies, two were randomised controlled trials (RCTs)
satisfying the inclusion criteria (Goldman 2001; Kikuchi 2009),
and the other five were controlled clinical trials (CCTs) (Patte
2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010; Wössmann
2003).
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Figure 1. Study flow diagram of review update
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Included studies
All seven included trials evaluated urate oxidase as a preventive
measure for tumour lysis syndrome. We identified no clinical trial
investigatingurate oxidase for treatment of tumour lysis syndrome.
We give details of the included trials in the ’Characteristics of
included studies’ tables and summarise the details below.
Six included trials compared urate oxidase against allopurinol
as the control treatment in parallel group designs (Goldman
2001; Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003). The remaining one included trial compared
different doses of urate oxidase (Kikuchi 2009). Four trials used
rasburicase (Goldman 2001; Kikuchi 2009; Rényi 2007; Sánchez
Tatay 2010)while the remaining three trials usedUricozyme (Patte
2002; Pui 1997;Wössmann 2003). Four included trials (Goldman
2001; Patte 2002; Pui 1997; Rényi 2007) used a standard al-
kaline hyperhydration regimen in both the intervention and the
control groups, while one trial (Wössmann 2003) used alkalinisa-
tion only in the control group. The remaining two trials (Kikuchi
2009; Sánchez Tatay 2010) did not mention alkalinisation. Six
trials (Goldman 2001; Kikuchi 2009; Patte 2002; Pui 1997; Rényi
2007; Wössmann 2003) initiated urate oxidase before the start of
chemotherapy, lasting for three to seven days. One trial (Sánchez
Tatay 2010) did not mention the duration of therapy.
None of the five included non-randomised, controlled clinical tri-
als used a concurrent control group. Four trials used a histori-
cal control group (Pui 1997; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003), and one trial used aggregate participant data
from trials of other study groups as a retrospective analysis (Patte
2002).
The RCT (Goldman 2001) comparing rasburicase with allopuri-
nol included a total of 27 children in the intervention group and
25 participants in the control group. This trial included children
only (aged 0.3 to 17 years) (Goldman 2001). The RCT compar-
ing different doses of rasburicase included a total of 15 partici-
pants in the low-dose group (0.15 mg/kg) and 15 participants in
the high-dose group (0.2 mg/kg) (Kikuchi 2009). This trial also
included children only (aged 0 to 17 years) (Kikuchi 2009). The
five CCTs comparing urate oxidase with allopurinol included a
total of 429 participants in the intervention groups and 563 par-
ticipants in the control groups. All five CCTs included children
only. Two of these trials reported a median age of 4.5 to 5.6 years
in the intervention groups and 5.7 to 6 years in the control groups
(Pui 1997; Rényi 2007). The remaining three trials (Patte 2002;
Sánchez Tatay 2010; Wössmann 2003) did not mention the age
distribution of the participants.
The types of malignancies included in all trials were similar. The
RCT comparing rasburicase and allopurinol recruited participants
with stage three or four non-Hodgkin’s lymphoma, acute lym-
phoblastic leukaemia (ALL) with high white blood cell (WBC)
counts, and participants with leukaemia or lymphoma with hy-
peruricaemia (Goldman 2001). The RCT comparing high-dose
and low-dose rasburicase recruited participants with stage four
non-Hodgkin’s lymphoma, stage three non-Hodgkin’s lymphoma
with large lymph node or high lactate dehydrogenase (LDH), and
acute leukaemia with high WBC (Kikuchi 2009). All five CCTs
included participants with haematological malignancies who were
at high risk of tumour lysis syndrome, with just minor differences
in the inclusion criteria among these trials (for details, please refer
to the ’Characteristics of included studies’ tables).
For outcome measures, only one study reported incidence of
clinical tumour lysis syndrome (Wössmann 2003). Five studies
(Goldman 2001; Kikuchi 2009; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003) reported on all-cause mortality. Five studies
(Goldman 2001; Kikuchi 2009; Patte 2002; Rényi 2007; Sánchez
Tatay 2010) also reported on mortality due to tumour lysis syn-
drome. All seven included studies reported frequency of renal fail-
ure requiring renal replacement therapy (Goldman 2001; Kikuchi
2009; Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003), two studies reported frequency of normalisa-
tion of serum uric acid (Goldman 2001; Kikuchi 2009), one study
reported area under curve (AUC) of serum uric acid (Goldman
2001), and four studies reported serial uric acid levels (Kikuchi
2009; Pui 1997; Rényi 2007; Sánchez Tatay 2010). Five studies
reported adverse events (Goldman 2001; Kikuchi 2009; Pui 1997;
Rényi 2007; Sánchez Tatay 2010).
Excluded studies
We excluded three RCTs evaluating urate oxidase for prevention
of tumour lysis syndrome as they recruited adult participants only
and did not include paediatric participants (Cortes 2010; Ishizawa
2009; Vadhan-Raj 2012).
Risk of bias in included studies
In general, none of the included trials were of highmethodological
quality. The two RCTs were quite small, recruiting only 30 to 52
participants (Goldman 2001; Kikuchi 2009).We describe the risk
of bias in the ’Characteristics of included studies’ tables, Figure 2,
and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Allocation
All five CCTs (Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay
2010; Wössmann 2003) included in this review were not ran-
domised trials and selection bias was likely present. The RCT
Kikuchi 2009 did not report random sequence generation or con-
cealment. We were uncertain whether there was high risk of selec-
tion bias. Random sequence generation and randomisation con-
cealment were likely to be adequate in the trial by Goldman as the
randomisation code was computer-generated (Goldman 2001).
Blinding
There was no blinding of participants, care providers, or outcome
assessors in all five included CCTs (Patte 2002; Pui 1997; Rényi
2007; Sánchez Tatay 2010; Wössmann 2003). Also, two of the
included RCTs (Goldman 2001; Kikuchi 2009) did not blind
participants, care providers, or outcome assessors, which might
introduce performance and detection biases.
Incomplete outcome data
There were dropouts with incomplete data in both included RCTs
(Goldman 2001; Kikuchi 2009). However, dropouts constituted
a very low proportion of participants in one study (Kikuchi 2009)
and were unlikely to cause significant attrition bias. Nevertheless,
we considered the RCT by Goldman to have a high risk of bias as
there were differences in the dropout rate between the intervention
and the control groups, and more than 10% of the participants
in the control group had incomplete follow up (Goldman 2001).
One CCT also had incomplete data for a large proportion of
participants and had high risk of attrition bias (Rényi 2007). The
remaining four CCTs had no dropouts (Patte 2002; Pui 1997;
Sánchez Tatay 2010; Wössmann 2003).
Selective reporting
It was unclear whether there was selective reporting of outcomes
in all included studies as the trial protocols were not available (
Goldman 2001; Kikuchi 2009; Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010; Wössmann 2003).
Other potential sources of bias
In all studies, there was a high risk of other bias. The interven-
tion and comparison groups were not comparable at baseline in
four studies, which might result in high risk of bias (Goldman
2001; Kikuchi 2009; Rényi 2007; Wössmann 2003). Two studies
(Patte 2002; Sánchez Tatay 2010) did not report some important
baseline characteristics, so the comparability of their intervention
and comparison groups was not certain. For non-randomised con-
trolled trials, failure of adjustment of potential confounders re-
sulted in high risk of bias (Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010; Wössmann 2003). The use of historical con-
trols in four trials (Pui 1997; Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003) may have biased the results in favour of the
newer treatment because of improvement in supportive care. In
one CCT (Patte 2002), chemotherapy treatments were different
in different centres in different locations, and this may have caused
bias.
Effects of interventions
Urate oxidase versus allopurinol
Six included studies compared urate oxidase with allopurinol for
prevention of tumour lysis syndrome. One study was an RCT
(Goldman 2001), and the other five studies were CCTs (Patte
2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010; Wössmann
2003).
Primary outcome
Incidence of clinical tumour lysis syndrome
One CCT (Wössmann 2003) that reported this outcome did not
find any significant difference between the group that received
Uricozyme and the group that received allopurinol. (Sixteen out
of 130 participants in the Uricozyme group versus 35 out of 218
participants in the allopurinol group developed tumour lysis syn-
drome (TLS); risk ratio (RR) 0.77, 95% confidence intervals (CI)
0.44 to 1.33; P = 0.34; intention-to-treat (ITT) analysis; Analysis
1.1; Figure 4.) This study also reported results for the subgroup
of participants with acute B lymphoblastic leukaemia (B-ALL)
and found no significant difference between the intervention and
the control groups. (Five out of 53 participants in the Uricozyme
group versus 16 out of 78 participants in the allopurinol group
developed TLS; RR 0.46, 95% CI 0.18 to 1.18; P = 0.11; ITT
analysis; Analysis 1.2.)
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Figure 4. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.1 Incidence of
clinical tumour lysis syndrome
Secondary outcomes
Incidence of laboratory tumour lysis syndrome
None of the included trials reported this outcome.
All-cause mortality
The RCT (Goldman 2001) showed slightly lower mortality in the
group that received rasburicase compared with the group that re-
ceived allopurinol, but this was not statistically significant. (None
of the 27 participants in the rasburicase group versus 2 out of
25 participants in the allopurinol group died; Fisher’s exact test
P = 0.23; ITT analysis; Analysis 1.3.) The two participants in
the allopurinol group died from Pseudomonas sepsis and intracere-
bral haemorrhage, respectively. All-causemortality was available in
three CCTs, two of which did not have anymortality (Rényi 2007;
Sánchez Tatay 2010), and the third one reported four deaths in the
control group (Wössmann 2003). The study reported the deaths
to be treatment-related, but did not specify the actual cause. The
pooled result of the three CCTs showed no significant difference
in all-cause mortality between the intervention and the control
groups. (None of the 158 participants in the urate oxidase group
versus four out of 248 participants in the allopurinol group died;
RR 0.19, 95% CI 0.01 to 3.42; P = 0.26; ITT analysis; Analysis
1.3.)
Mortality due to tumour lysis syndrome
The RCT (Goldman 2001) did not find any mortality due to tu-
mour lysis syndrome in either the intervention group (total of 27
participants) or control group (total of 25 participants) (ITT anal-
ysis) (Analysis 1.4). However, pooled results of three CCTs (Patte
2002; Rényi 2007; Sánchez Tatay 2010) showed a significantly
lower mortality due to tumour lysis syndrome in the group that
received Uricozyme compared with the group that received allop-
urinol, (None of the 180 participants in the intervention group
versus 11 out of 216 participants in the control group died due
to TLS; RR 0.05, 95% CI 0.00 to 0.89; P = 0.04; ITT analysis;
Analysis 1.4; Figure 5.)
Figure 5. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.4 Mortality
due to tumour lysis syndrome
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Renal failure requiring renal replacement therapy
TheRCT (Goldman 2001) showed no significant difference in the
frequency of renal failure between the intervention and the con-
trol groups. (None of the 27 participants in the rasburicase group
versus one out of 25 participants in the allopurinol group had re-
nal failure; Fisher’s exact test P = 0.48; ITT analysis; Analysis 1.5.)
In contrast, pooled results of five CCTs (Patte 2002; Pui 1997;
Rényi 2007; Sánchez Tatay 2010; Wössmann 2003) showed sig-
nificantly lower frequency of renal failure requiring renal replace-
ment therapy in participants who received urate oxidase compared
with those who received allopurinol. (Twelve out of 429 partici-
pants in the intervention group versus 65 out of 563 participants
in the control group developed renal failure; I² = 62%; RR 0.26,
95% CI 0.08 to 0.89; P = 0.03; ITT analysis; Analysis 1.5; Figure
6.) One CCT (Wössmann 2003) reported results of a subgroup
of participants with B-ALL and showed lower frequency of renal
failure in the intervention group, but the difference was not sta-
tistically significant. (Two out of 53 participants in the interven-
tion group versus 12 out of 78 participants in the control group
developed renal failure; RR 0.25, 95% CI 0.06 to 1.05; P = 0.06;
ITT analysis; Analysis 1.6.)
Figure 6. Forest plot of comparison: 1 Urate oxidase compared with allopurinol, outcome: 1.5 Renal failure
requiring renal replacement therapy
Normalisation of uric acid level
The RCT (Goldman 2001) showed significantly higher frequency
of uric acid normalisation at four hours in the participants who
received rasburicase compared with participants who received al-
lopurinol. (Ten out of 10 participants in the intervention group
versus zero out of nine participants in the control group had nor-
malisation of uric acid level; Fisher’s exact test P < 0.001; not ITT
analysis.)
Duration before normalisation of serum uric acid level
None of the included trials reported this outcome.
Area under curve (AUC) of serum uric acid level
The RCT (Goldman 2001) reported a significantly lower AUC
of serum uric acid at four days in the intervention group com-
pared with the control group (mean AUC 128 mg/dLhr in 27
participants in the intervention group versus 329 mg/dLhr in 25
participants in the control group; mean difference (MD) -201.00
mg/dLhr, 95% CI -258.05 mg/dLhr to -143.95 mg/dLhr; P <
0.00001; ITT analysis; Analysis 1.7.) The RCT also reported re-
sults of different subgroups and found significantly lower AUC of
serum uric acid at four days in the intervention group compared
with the control group in participants with leukaemia (mean AUC
141 mg/dLhr in 20 participants in the intervention group ver-
sus 361 mg/dLhr in 19 participants in the control group; MD -
220.00 mg/dLhr, 95% CI -286.67 mg/dLhr to -153.33 mg/dLhr;
P < 0.00001; ITT analysis; Analysis 1.8), lymphoma (mean AUC
92 mg/dLhr in seven participants in the intervention group ver-
sus 224 mg/dLhr in six participants in the control group; MD -
132.00 mg/dLhr, 95% CI -185.47 mg/dLhr to -78.53 mg/dLhr;
P < 0.00001; ITT analysis; Analysis 1.9), baseline hyperuricaemia
participants (mean AUC 162 mg/dLhr in 10 participants in the
intervention group versus 440 mg/dLhr in nine participants in the
control group; MD -278.00 mg/dLhr, 95% CI -373.69 mg/dLhr
to -182.31 mg/dLhr; P < 0.00001; ITT analysis; Analysis 1.10),
and participants with normal baseline uric acid (mean AUC 108
mg/dLhr in 17 participants in the intervention group versus 348
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mg/dLhr in 16 participants in the control group; MD -240.00
mg/dLhr, 95% CI -340.95 mg/dLhr to -139.05 mg/dLhr, P <
0.00001; ITT analysis; Analysis 1.11.)
Serial uric acid level
Three CCTs reported serial uric acid levels (Pui 1997; Rényi
2007; Sánchez Tatay 2010). All three CCTs reported results on the
first two days after urate oxidase, while two studies (Rényi 2007;
SánchezTatay 2010) reported results up to four days and one study
(Rényi 2007) reported results up to 12 days. The pooled results
showed significantly lower uric acid level in the intervention group
compared with the control group at two days (mean uric acid level
1.02mg/dL in 147 participants the intervention group versus 3.25
mg/dL in 147 participants in the control group; I² = 87%; MD
-3.80 mg/dL, 95% CI -7.37 mg/dL to -0.24 mg/dL; P = 0.04;
not ITT analysis; < 70% of participants had outcomes available
for Rényi 2007; results susceptible to bias; Analysis 1.13), three
days (mean uric acid level 0.52 mg/dL in 28 participants in the
intervention group versus 4.66 mg/dL in 19 participants in the
control group; I² = 89%; MD -3.13 mg/dL, 95% CI -6.12 mg/dL
to -0.14 mg/dL; P = 0.04; not ITT analysis; < 70% of participants
had outcomes available for Rényi 2007; results susceptible to bias;
Analysis 1.14), four days (mean uric acid level 0.24 mg/dL in 28
participants in the intervention group versus 4.41 mg/dL in 17
participants in the control group; MD -4.60 mg/dL, 95% CI -
6.39 mg/dL to -2.81 mg/dL; P < 0.00001; not ITT analysis; <
70%of participants had outcomes available for Rényi 2007; results
susceptible to bias; Analysis 1.15), and seven days (mean uric acid
level 1.43 mg/dL in 12 participants in the intervention group
versus 3.17 mg/dL in four participants in the control group; MD
-1.74 mg/dL, 95% CI -3.01 mg/dL to -0.47 mg/dL; P = 0.007;
not ITT analysis; < 70% of patients had outcomes available for
Rényi 2007; results susceptible to bias; Analysis 1.17), but not
significant at one day (mean uric acid level 1.37 mg/dL in 147
participants in the intervention group versus 3.94 mg/dL in 151
participants in the control group; I² = 94%; MD -3.00 mg/dL,
95% CI -7.61 mg/dL to 1.60 mg/dL; P = 0.2; not ITT analysis;
< 70% of participants had outcomes available for Rényi 2007;
results susceptible to bias; Analysis 1.12), five days (mean uric
acid level 0.44 mg/dL in 12 participants in the intervention group
versus 1.46 mg/dL in two participants in the control group; MD
-1.02 mg/dL, 95% CI -2.24 mg/dL to 0.20 mg/dL; P = 0.1; not
ITT analysis; < 70% of participants had outcomes available for
Rényi 2007; results susceptible to bias; Analysis 1.16), and 12
days (mean uric acid level 2.34 mg/dL in 12 participants in the
intervention group versus 3.14 mg/dL in eight participants in the
control group; MD -0.80 mg/dL, 95% CI -2.51 mg/dL to 0.91
mg/dL; P = 0.36; not ITT analysis; Analysis 1.18).
Adverse events
The RCT (Goldman 2001) and three CCTs (Pui 1997; Rényi
2007; SánchezTatay 2010) reported frequency of adverse effects in
the intervention and control groups. The RCT showed no signifi-
cant differences between the intervention and the control groups.
(One out of 27 participants in the intervention group versus none
of the 25 participants in the control group had an adverse event;
Fisher’s exact test P = 1.0; ITT analysis.) The adverse event re-
ported was haemolysis. The pooled results fromCCTs showed sig-
nificantly higher frequency of adverse effects in participants who
received urate oxidase. (Thirteen out of 186 participants in the
intervention group verses none of the 159 participants in the con-
trol group had adverse events; RR 9.10, 95% CI 1.29 to 64.00;
P = 0.03; I² = 0%; ITT analysis; Analysis 1.19.) Adverse events
reported in the intervention group included allergic reaction (six
participants), methaemoglobinaemia (one participant), fever (two
participants), nausea (one participant), abdominal pain (one par-
ticipant), andmucositis (two participants). It should be noted that
the Pui 1997 and Rényi 2007 studies included additional partici-
pants in this analysis (see the ’Characteristics of included studies’
tables for more information).
High-dose urate oxidase versus low-dose urate
oxidase
One RCT (Kikuchi 2009) compared urate oxidase (rasburicase)
given in high dose (0.2 mg/kg/day for five days) versus low dose
(0.15 mg/kg/day for five days) .
Primary outcome
Incidence of clinical tumour lysis syndrome
The RCT did not report this outcome.
Secondary outcomes
Incidence of laboratory tumour lysis syndrome
The RCT did not report this outcome.
All-cause mortality
The RCT (Kikuchi 2009) reported no significant difference in all-
cause mortality between the high-dose and the low-dose groups.
(None of the 15 participants in the high-dose group versus one of
the 15 participants in the low-dose group died; Fisher’s exact test
P = 1.0; ITT analysis.) The death in the low-dose group was due
to cerebral haemorrhage, brain oedema, and brain herniation.
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Mortality due to tumour lysis syndrome
The RCT (Kikuchi 2009) reported no mortality due to TLS in
both the high-dose group (15 participants) and the low-dose group
(15 participants) (ITT analysis).
Renal failure requiring renal replacement therapy
The RCT (Kikuchi 2009) reported no renal failure due to TLS
in both the high-dose group (15 participants) and the low-dose
group (15 participants) (ITT analysis).
Normalisation of uric acid level
The RCT (Kikuchi 2009) showed no significant difference be-
tween the high-dose and the low-dose groups. (All participants
(14) in the high-dose group versus 14 out of 15 participants in
the low-dose group had normalisation of uric acid level; RR 1.07,
95% CI 0.89 to 1.28; P = 0.49; not ITT analysis; Analysis 2.1.)
Duration before normalisation of serum uric acid level
The included RCT did not report this outcome.
AUC of serum uric acid level
The included RCT did not report this outcome.
Serial uric acid level
The RCT (Kikuchi 2009) reported the percentage reduction of
uric acid level at four hours and did not find any significant differ-
ence between the high-dose and the low-dose groups (mean per-
centage reduction in uric acid level 92.9% in 14 participants in
the high-dose group versus 84.8% in 15 participants in the low-
dose group; MD 8.10%, 95% CI -0.99% to 17.19%; P = 0.08;
not ITT analysis; Analysis 2.2).
Adverse events
The RCT (Kikuchi 2009) did not show any significant difference
in the frequency of adverse events between the high-dose group
(two out of 15 participants) and the low-dose groups (four out of
15 participants) (ITT analysis) (Analysis 2.3). Adverse events in-
cluded allergic reaction (three participants), haemolysis (one par-
ticipant), and anaemia (two participants).
Sensitivity analysis and cost-benefit analysis
We planned to do sensitivity analysis for heterogeneous results by
excluding outlying results. We could not identify any obvious out-
liers, and therefore did not perform this sensitivity analysis. Since
there was only one RCT with adequate allocation concealment,
which we did not include in a pooled analysis, we did not perform
sensitivity analysis for this. Since we identified no high-quality
data on effectiveness, we did not perform a cost-benefit analysis.
D I S C U S S I O N
This is an update of the original systematic review. Conclu-
sions regarding efficacy outcomes did not change, whereas for ad-
verse effects they did. Although numerous uncontrolled studies
have found that urate oxidase can lower serum uric acid levels
quickly and sometimes dramatically, we found little evidence from
randomised controlled trials (RCTs) or controlled clinical trials
(CCTs) supporting its effectiveness in preventing or treating tu-
mour lysis syndrome (TLS) in children with cancer. Only two
RCTs (Goldman 2001; Kikuchi 2009) and five CCTs (Patte 2002;
Pui 1997; Rényi 2007; Sánchez Tatay 2010; Wössmann 2003)
were available on the prophylaxis of tumour lysis syndrome. There
is currently no trial evaluating urate oxidase for treatment of es-
tablished tumour lysis syndrome.
Summary of main results
Urate oxidase versus allopurinol
Six included studies compared urate oxidase with allopurinol for
the prevention of tumour lysis syndrome. One study was an RCT
(Goldman 2001), and the other five studies were CCTs (Patte
2002; Pui 1997; Rényi 2007; Sánchez Tatay 2010; Wössmann
2003). One CCT (Wössmann 2003) reported the incidence of
clinical tumour lysis syndrome and did not find significant differ-
ence between the group that received Uricozyme and the group
that received allopurinol. The RCT (Goldman 2001) showed no
significant difference in all-cause mortality between the group that
received rasburicase and the group that received allopurinol. The
pooled result of the three CCTs (Rényi 2007; Sánchez Tatay 2010;
Wössmann 2003) also showedno significant difference in all-cause
mortality between the intervention and the control groups. The
RCT (Goldman 2001) did not find any mortality due to TLS in
either the intervention group or the control group. However, the
pooled result of the three CCTs (Patte 2002; Rényi 2007; Sánchez
Tatay 2010) showed a significantly lower mortality due to TLS
in the group that received Uricozyme compared with the group
that received allopurinol. The RCT (Goldman 2001) showed no
significant difference in the frequency of renal failure between the
intervention and the control groups. In contrast, pooled results
of five CCTs (Patte 2002; Pui 1997; Rényi 2007; Sánchez Tatay
2010; Wössmann 2003) showed significantly lower frequency of
renal failure requiring renal replacement therapy in participants
who received urate oxidase compared with those who received al-
lopurinol. However, heterogeneity was present in this analysis.
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The RCT (Goldman 2001) showed significantly higher frequency
of uric acid normalisation at four hours in the participants who re-
ceived rasburicase compared with participants who received allop-
urinol. All included trials did not report the duration before nor-
malisation of serum uric acid level. The RCT (Goldman 2001) re-
ported a significantly lower AUCof serumuric acid at 4 days in the
intervention group compared with the control group. ThreeCCTs
reported serial uric acid levels (Pui 1997; Rényi 2007; Sánchez
Tatay 2010). All three CCTs reported results on the first two days
after urate oxidase, while two studies (Rényi 2007; Sánchez Tatay
2010) reported results up to four days, and one study (Rényi 2007)
reported results up to 12 days. The pooled results showed signif-
icantly lower uric acid levels in the intervention group compared
with the control group at two days, three days, four days, and seven
days, but the differences were not significant at one day, five days,
and 12 days. Heterogeneity was present in some of these analy-
ses. The RCT (Goldman 2001) and three CCTs (Pui 1997; Rényi
2007; Sánchez Tatay 2010) reported frequency of adverse effects
in the intervention and the control groups. The RCT showed no
significant differences between the intervention and the control
groups. The adverse event reportedwas haemolysis. The pooled re-
sults from the three CCTs showed significantly higher frequency of
adverse effects in participants who received urate oxidase. Adverse
events reported in the intervention group included allergic reac-
tion (six participants), methaemoglobinaemia (one participant),
fever (two participants), nausea (one participant), abdominal pain
(one participant), and mucositis (two participants).
High-dose versus low-dose urate oxidase
We included one RCT that compared high-dose versus low-dose
rasburicase (Kikuchi 2009). The trial did not report the incidence
of TLS. The trial reported no significant difference in all-cause
mortality between the high-dose and the low-dose groups. There
was no mortality due to TLS in both the high-dose and the low-
dose groups. There was no renal failure due to TLS in both groups.
There was no significant difference in normalisation of uric acid
level between the high-dose and the low-dose groups. The included
RCT did not report the duration before normalisation of serum
uric acid level or the AUC of serum uric acid level. The trial
reported the percentage reduction of uric acid level at four hours
and did not find significant difference between the two groups.
There was no significant difference in the frequency of adverse
events between the two groups. Adverse events included allergic
reaction (three participants), haemolysis (one participant), and
anaemia (two participants).
Overall completeness and applicability of
evidence
Although urate oxidase is widely used in paediatric cancer patients
for prevention of tumour lysis syndrome, high-quality evidence
of its efficacy is limited. The only RCT comparing urate oxidase
with allopurinol (Goldman 2001) did not report the important
outcome of clinical tumour lysis syndrome. Although participants
who received rasburicase had significantly lower exposure to uric
acid (lower AUC and higher chance of uric acid normalisation)
compared with participants who received allopurinol in the RCT
(Goldman 2001), we were not entirely certain whether this trans-
lated into significant clinical benefits. Although hyperuricaemia is
related to tumour lysis syndrome, this trial failed to show any sig-
nificant difference between the treatment and the control groups
in all-cause mortality or mortality related to tumour lysis syn-
drome or renal failure requiring renal replacement therapy. Be-
cause of the paucity of evidence fromRCT, we also includedCCTs
in the current systematic review. However, all five CCTs identified
were of unsatisfactory methodological quality. Although mortality
due to tumour lysis syndrome and incidence of renal failure were
found to be significantly lower in participants who received urate
oxidase, the conclusion from CCTs has to be treated with caution
in view of high risk of biases.
On the other hand, due to inadequate sample size in the existing
trials, the absence of significant clinical benefits of urate oxidase
may be a false negative result. Therefore, we cannot ignore the po-
tential benefits of urate oxidase in children with malignancy based
on the current available evidence, especially in view of its probable
effectiveness in reducing serum uric acid, which is an important
surrogate outcome. Further trials of larger sample size are needed
to clarify the role of urate oxidase. Assuming a mortality rate of
0.9% (Annemans 2003a) and that urate oxidase is effective in re-
ducing mortality by half, the number of cancer patients needed to
treat to prevent one death is 223, and the sample size required to
achieve a power of 80% in detecting a reduction in mortality at a
5% level of significance is estimated to be 856 patients.
There was only one RCT comparing different doses of rasburicase
(Kikuchi 2009). The results were consistent with previous uncon-
trolled studies and controlled clinical trials; comparing rasburic-
ase at 0.15 mg/kg and 0.2 mg/kg showed a dramatic reduction
in serum uric acid level in both arms. However, the RCT did not
report the important outcome of incidence of clinical tumour ly-
sis syndrome, and this small trial was not adequately powered to
address the other clinically important outcomes of mortality or
renal failure. Although there was no significant difference in any of
the outcomes between the two groups, we are not certain whether
a higher and lower dose of rasburicase are really equivalent be-
cause of the small sample size. Likewise, there is uncertainly about
whether the higher dose is associated with more adverse effects.
Although not eligible for inclusion in this review, there is a study
that has addressed the cost-effectiveness of rasburicase (Annemans
2003b). This study concluded that rasburicase was cost-effective
for prevention of tumour lysis syndrome in children, and rasburi-
case for the treatment of tumour lysis syndrome in children was
cost-saving. However, this conclusion was based on the assump-
tion that rasburicase is 60% to 100% effective in the prevention
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of tumour lysis syndrome, which was not in fact based on high-
quality trial evidence. As the effectiveness of urate oxidase in the
prevention or treatment of tumour lysis syndrome has yet to be
established, its cost-effectiveness remains uncertain.
Quality of the evidence
Apart from limitations in the number of RCTs reporting clini-
cally relevant outcomes and inadequate power to evaluate these
outcomes, the trials included in the current review had a number
of methodological flaws and were prone to bias. We considered
none of the included studies to have low risk of bias in all aspects
assessed. In both RCTs, the treatment and the control groups were
not comparable at baseline, which casts doubt on the success of
randomisation and increased the probability of confounding. One
of the RCTs included did not report the random sequence genera-
tion or allocation concealment, which are important to minimise
selection bias (Kikuchi 2009). The other RCT had more drop-
outs in the control arm than in the treatment arm, which might
have caused attrition bias (Goldman 2001). None of the included
RCTs attempted to blind the participants, physicians, or outcome
assessors, which might have introduced performance and detec-
tion biases. Trial protocols were not available, and it was uncertain
whether there was reporting bias in the RCTs.
In addition, all five CCTs included were also of unsatisfac-
tory methodological quality (Patte 2002; Pui 1997; Rényi 2007;
Sánchez Tatay 2010; Wössmann 2003). There was a high risk of
selection bias as participants were not randomly allocated to treat-
ment groups. Performance and detection biases were also likely as
there was no blinding. Reporting bias was uncertain as trial proto-
cols were not available. There was a high risk of attrition bas in one
CCT, which had a lot of missing data (Rényi 2007). The results
from the four historical controlled trials (Pui 1997; Rényi 2007;
SánchezTatay 2010;Wössmann 2003)were prone to bias from the
advancement of supportive care with time. The remaining CCT
(Patte 2002) was actually a retrospective review of data from trials
of chemotherapy protocols comparing different treatments from
different study groups at different locations; therefore, it suffered
from bias due to different practices in different centres. The inter-
vention and comparison groups were not comparable at baseline
in two studies, whichmight result in high risk of bias (Rényi 2007;
Wössmann 2003). Two studies (Patte 2002; Sánchez Tatay 2010)
did not report some important baseline characteristics, so compa-
rability of the intervention and comparison groups was uncertain.
None of the included CCTs took into consideration and adjusted
for potential confounding factors in their analyses; hence, their
results were susceptible to confounding by known and unknown
factors.
Potential biases in the review process
We focused our search tomajor English electronic databases; there-
fore, non-English literaturemight be underrepresented andmissed
in the review. Because the search was focused on RCTs and CCTs,
we could have missed some further historical controlled trials.
Publication bias was also possible.
Agreements and disagreements with other
studies or reviews
As far as we know, this is the only systematic review evaluating the
effectiveness of urate oxidase for prevention and treatment of tu-
mour lysis in children with cancer. There was a review on tumour
lysis syndrome with targeted therapy and the role of rasburicase
(Bose 2011). The authors performed a search on MEDLINE in
February 2011 and included RCTs, CCTs, and single-arm stud-
ies of rasburicase in both children and adults. That review had a
similar conclusion to the current review, that although there was
a wealth of evidence suggesting that rasburicase is effective in cor-
recting hyperuricaemia, prospective trials showing that it improves
hard outcomes, such as acute renal failure, need for dialysis, and
mortality, are lacking. More randomised controlled trials evaluat-
ing clinically relevant outcomes are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Thus far, the paucity of high-quality studies precludes firm recom-
mendations. Although there is some evidence that urate oxidase
might bemore effective than allopurinol in reducing the frequency
of hyperuricaemia and the exposure to high serum uric acid, it is
still uncertain whether the routine use of urate oxidase is effec-
tive for the prevention or treatment of tumour lysis syndrome, or
a reduction in mortality or renal failure associated with tumour
lysis syndrome in children with cancer. The potential benefit of
urate oxidasemight be its effectiveness in reducing serumuric acid,
which is an important surrogate outcome. It is unclear which type
of urate oxidase (rasburicase or Uricozyme) is superior in terms of
efficacy andwhat dosage regimen or treatment duration is optimal.
On the other hand, urate oxidase may be associated with potential
adverse effects, such as haemolysis or hypersensitivity. Clinicians
who wish to use urate oxidase should weigh the potential benefits
of reducing serum uric acid levels and the uncertain benefits in
preventing renal failure or mortality from tumour lysis syndrome
against the potential risk of adverse effects.
Implications for research
There is a paucity of evidence from randomised controlled trials
assessing urate oxidase for the prevention and treatment of tu-
mour lysis syndrome in children with cancer. The existing trials
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are of small size and low methodological quality. Further high-
quality RCTs of larger sample size are needed to assess the effec-
tiveness of urate oxidase in children, especially high-risk patients
who are more likely to benefit. High-risk patients can include
those with high tumour burden or turn-over (such as high ini-
tial white blood cell counts for leukaemia, or Burkitt lymphoma,
high-stage lymphoma, or lymphoma with bulky disease), and pa-
tients with baseline hyperuricaemia, renal impairment, hypocal-
caemia, or hypophosphataemia. Trials should assess patient-ori-
entated outcomes, such as incidence of clinical tumour lysis syn-
drome, mortality, or frequency of renal failure. Although blinding
of participants and clinicians for comparison of intravenous urate
oxidase and oral allopurinol is difficult, it can be attempted with
the use of a double placebo, to minimise performance biases. The
effectiveness and safety of different forms of urate oxidase in dif-
ferent dosage regimens should also be investigated further.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Goldman 2001
Methods Design: RCT
Randomisation method: stratified randomisation, computer-generated randomisation
code
Stratification factor: according to uric acid level (< 8 mg/dL or ≥ 8 mg/dL)
Participants Inclusion criteria: paediatric participants < 18 years with leukaemia and lymphoma
deemed to have a high risk of tumour lysis syndrome: Murphy stage III or IV non-
Hodgkin’s lymphoma,ALLwithWBC≥ 25,000/uL, childhood lymphomaor leukaemia
with uric acid level of ≥ 8 mg/dL. Participants must have received chemotherapeutic
agents not investigational in nature, with minimum life expectancy of 4 weeks, and
ECOG performance scale ≤ 3 or Karnofsky scale ≥ 30%
Exclusion criteria: participants previously treated with rasburicase or Uricozyme, treat-
ment with allopurinol within 7 days, significant history of documented asthma, atopy,
or G6PD deficiency
Number of participants (intervention/comparison): 27/25
Number of boys (intervention/comparison): 16/18
Age (intervention/comparison): (mean) 7.1 (range = 0.3 to 17)/7.8 (range = 0.5 to 16)
years
Underlying haematological malignancies (intervention/comparison): leukaemia 20/9;
lymphoma 7/6
Baseline creatinine (intervention/comparison): (mean) 0.6 (SD 0.33)/0.61 (SD 0.3) mg/
dL
Baseline uric acid (intervention/comparison): (mean) 7.7 (SD 3.5)/6.8 (SD 3.4) mg/dL
Baseline potassium (intervention/comparison): (mean) 4.18 (SD 0.71)/3.85 (SD 0.52)
mg/dL
Baseline phosphate (intervention/comparison): (mean) 4.62 (SD 1.39)/4.15 (SD 1.11)
mg/dL
Baseline calcium (intervention/comparison): (mean) 8.92 (SD 0.74)/8.67 (SD 0.7) mg/
dL
Baseline LDH (intervention/comparison): (mean) 1599 (SD 1022)/1393 (SD 1438) U/
L
Baseline WBC (intervention/comparison): (mean) 83.2 (SD 81)/91 (SD 115) x109/L
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi over 30 minutes daily
for 5 to 7 days
Treatment regime in comparison group: allopurinol 300 mg/m²/day or 10 mg/kg/day
divided every 8 hours for 5 to 7 days
Cointerventions: hydration3L/m²/day, iv sodiumbicarbonate at investigator’s discretion
Outcomes • All-cause mortality
• Mortality due to tumour lysis syndrome
• Incidence of renal failure requiring renal replacement therapy
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• Frequency of normalisation of serum uric acid level
• Area under curve (AUC) of serum uric acid level
• Frequency of adverse effects (haemolysis)
Notes Duration of follow up: 2 weeks
Number of dropouts (intervention/comparison): 1 (haemolysis)/3 (2 died; 1 did not
start chemotherapy)
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because serum uric acid level was higher
in the treatment group
Whether outcomes were clearly defined: yes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...treatment (rasburicase or allop-
urinol) was randomly allocated to patients
according to a computer-generated ran-
domization code schema”
Allocation concealment (selection bias) Low risk Quote: “Via telephone entry, treatment
(rasburicase or allopurinol) was randomly
allocated to patients according to a
computer-generated randomization code
schema”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants knew which treatment they
were allocated, and care providers knew
which treatment a participant was allocated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk 4% of participants in the treatment group
and 12% of participants in the control
group did not complete treatment or fol-
low up
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because serum uric acid level was
higher in the treatment group,whichmight
introduce bias
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Kikuchi 2009
Methods Design: RCT
Randomisation method: central randomisation, details not available
Stratification factor: baseline body weight (< 10 or ≥ 10 kg)
Participants Inclusion criteria: paediatric participants < 18 years with newly diagnosed haematological
malignancies with hyperuricaemia (uric acid > 7.5 mg/dL for participants ≥ 13 years;
uric acid > 6.5 mg/dL for participants < 13 years) or with a high tumour burden (defined
as non-Hodgkin’s lymphoma stage IV; NHL stage III with ≥ 1 lymph node or mass >
5 cm, or LDH ≥ 3 times the upper limit of normal) or acute leukaemia with WBC ≥
50,000/mm³ and LDH ≥ 3 times the upper limit of normal
ECOG performance scale ≤ 3 or Lansky score ≥ 30
Life expectancy ≥ 45 days
Exclusion criteria: administration of allopurinol within 72 hours; knownhistory of severe
allergy, severe asthma, or both; low birth weight (< 2500 g) or gestational age < 37 weeks;
previous therapy with urate oxidase; positive HBsAg, HCV antibodies, HIV-1 or HIV-
2 antibodies; severe disorders of the liver or kidney (ALT > 5 times the upper limit of
normal, total bilirubin > 3 times the upper limit of normal; creatinine > 3 times the upper
limit of normal); uncontrollable infection including viral infection; G6PD deficiency;
known family history of G6PD deficiency; known history of methaemoglobinaemia and
haemolysis
Number of participants (low-dose group/high-dose group): 15/15
Number of boys (low-dose group/high-dose group): 9/10
Age (low-dose group/high-dose group): (median) 11 (range = 1 to 17)/7 (range = 0 to
16) years
Underlying haematological malignancies (low-dose group/high-dose group): acute
leukaemia 9/13; lymphoma 6/2
Baseline hyperuricaemia (low-dose group/high-dose group): 8/5
Baseline creatinine (low-dose group/high-dose group): (mean) 52.3 (SD 22.6)/44.4 (SD
19.1) mg/dL
Interventions Intervention (type of urate oxidase): rasburicase in both groups (0.15 mg/kg versus 0.2
mg/kg)
Treatment regime in low-dose group: rasburicase 0.15 mg/kg ivi over 30 minutes daily
for 5 days
Treatment regime in high-dose group: rasburicase 0.2 mg/kg ivi over 30 minutes daily
for 5 days
Cointerventions: chemotherapy started 4 to 24 hours after the first dose of rasburicase
in both groups
Outcomes • All-cause mortality
• Mortality due to tumour lysis syndrome
• Incidence of renal failure requiring renal replacement therapy
• Frequency of normalisation of serum uric acid level
• Serial uric acid levels
• Frequency of adverse events
Notes Duration of follow up: 5 weeks
Number of dropouts (low-dose group/high-dose group): 1 (3 concomitant grade 4 ad-
verse events)/1 (lack of WBC result at baseline)
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Kikuchi 2009 (Continued)
The 2 groups may not be comparable at baseline because body weight was higher in
the low-dose group; baseline hyperuricaemia and diagnosis of lymphoma were more
frequent in the low-dose group
Whether outcomes were clearly defined: yes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly allocated to the
2 treatment groups by central randomisa-
tion, but details were not available
Allocation concealment (selection bias) Unclear risk This was not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants knew which treatment they
were allocated, and care providers knew
which treatment a participant was allocated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors knew which treatment
participants were assigned as this was an
open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6.7% of each group of participants did not
complete treatment or follow up, which
were explained. The low proportion of
dropout is unlikely to cause significant bias
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because body weight was higher
in the low-dose group; baseline hyperuri-
caemia and diagnosis of lymphoma were
more frequent in the low-dose group
Patte 2002
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants with stage III and IV B-cell NHL or L3 ALL
treated with the LMB89 protocol (intervention group), paediatric participants with
stage IV B-cell NHL or ALL treated with UKCCSG protocol (comparison group 1),
or paediatric participants with stage IV B-cell NHL or ALL treated with POG protocol
(comparison group 2)
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Patte 2002 (Continued)
Exclusion criteria: participants not treated in France excluded from intervention group
Number of participants (intervention/comparison 1/comparison 2): 152/63/123
Number of boys (intervention/comparison 1/comparison 2): not available
Age (intervention/comparison 1/comparison 2): not available
Underlying haematological malignancies: only data for intervention group available: B-
NHL stage III 257 out of 410; B-NHL stage IV 57 out of 410; L3 ALL 96 out of 410
Baseline renal failure (intervention/comparison 1/comparison 2): 21/410/not available
Baseline elevated LDH ≥ 2 x normal (intervention/comparison 1/comparison 2): 234/
410/not available
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison 1 and 2 (type of control): allopurinol
Treatment regime in intervention group: Uricozyme 50 to 100 U/kg/day for 5 to 7 days
Treatment regime in comparison groups: not available
Cointerventions: intervention group: alkaline hyperhydration 3 L/m²/day to obtain
urine output 100 to 120 ml/m²/hour and urine pH 7; not stated in comparison groups
Outcomes • Mortality due to tumour lysis syndrome
• Incidence of renal failure requiring renal replacement therapy
Notes Duration of follow up: 7 days
Number of dropouts (intervention/comparison 1/comparison 2): 0/0/0
Potential confounders were not described or adjusted
Comparability of the treatment groups at baseline was uncertain because some important
baseline characteristics of comparison groups were not available
Whether outcomes were clearly defined: yes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All outcomes
Low risk The outcome data were complete for the
groups of participants analysed
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Patte 2002 (Continued)
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk Comparability of the treatment groups at
baseline was uncertain because baseline
characteristics of comparison groups were
not available. Potential confounders were
not adjusted. Chemotherapy treatments
were different in different centres in differ-
ent locations, which may cause bias
Pui 1997
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants with non-B-cell ALL
Exclusion criteria: participants with history of allergy, G6PD deficiency or pregnancy,
or who had not received methotrexate or 6-mercaptopurine as preinduction therapy
Number of participants (intervention/comparison): 119/129
Number of boys (intervention/comparison): not available
Age (intervention/comparison): (median) 5.6/5.7 years
Underlying haematological malignancies (intervention/comparison): all non-B-cell ALL
Baseline WBC (intervention/comparison): (median) 11.7/13.8 x10 /L
Baseline uric acid (intervention/comparison): (median) 4.3/4.3 mg/dL
Baseline lactate dehydrogenase (intervention/comparison): (median) 1243/957 U/L
Baseline BUN (intervention/comparison): (median) 8.0/8.0 mg/dL
Baseline creatinine (intervention/comparison): (median) 0.5/0.5 mg/dL
Baseline calcium (intervention/comparison): (median) 9.4/9.4 mg/dL
Baseline phosphate (intervention/comparison): (median) 4.9/4.7 mg/dL
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison (type of control): allopurinol
Treatment regime in intervention group: Uricozyme 100 units/kg ivi over 30 minutes
daily for 5 days
Treatment regime in comparison group: allopurinol 300 mg/m²/day po for 5 to 13 days
Cointerventions: hydration with NaHCO to maintain urine pH≥ 6.5; oral phosphate
binders (aluminium hydroxide or calcium carbonate) were given to participants as indi-
cated
Outcomes • Incidence of renal failure requiring renal replacement therapy
• Serial uric acid levels
• Frequency of adverse effects
Notes Duration of follow up: 13 days
Number of dropouts (intervention/comparison): 0/0
Potential confounders were adjusted
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The intervention and the control groups appeared comparable at baseline
Whether outcomes were clearly defined: yes
The report of adverse events included additional 15 participants who had received an
incomplete course of Uricozyme
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All outcomes
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk Potential confounders were not adjusted.
Use of historical controlmay bias the results
in favour of the newer treatment because of
improvement in supportive care
Rényi 2007
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants aged 6 months to 18 years with a recent di-
agnosis of B-cell lineage ALL with an initial WBC ≥ 25,000/uL, or high-grade non-
Hodgkin’s lymphoma, or any type of ALL or NHL with a plasma uric acid≥ 480 mmol/
L and LDH > 500 IU/L, or either a creatinine or an LDH concentration > twice the
upper limit of normal
Exclusion criteria: history of clinically significant atopic allergy, bronchial asthma, G6PD
deficiency or any type of haemolytic anaemia, previous treatmentwith rasburicase or non-
recombinant urate oxidase, hypersensitivity reaction against ingredients of the present
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preparation used in the study, participation in another drug experiment, pregnancy or
lactation
Number of participants (intervention/comparison): 12/14
Number of boys (intervention/comparison): 6/6
Age (intervention/comparison): (median) 4.5/6
Underlying haematological malignancies (intervention/comparison): leukaemia 8/13;
lymphoma 4/1
Baseline creatinine (intervention/comparison): median 65 (range = 32 to 85)/80 (range
= 17 to 353) umol/L
Baseline uric acid (intervention/comparison): median 323 (range = 139 to 1059)/207
(range = 51 to 785) umol/L
Baseline phosphate (intervention/comparison): median 1.32 (range = 0.97 to 1.64)/1.
62 (range = 0.98 to 1.33) mmol/L
Baseline LDH (intervention/comparison): 1909 (range = 497 to 9760)/3193 (236 to
20,560) U/L
Baseline WBC (intervention/comparison): 51.8 (range = 2 to 651)/56 (range = 0.4 to
551) x109/L
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi over 30 minutes daily
for 5 days from day 1 of antineoplastic treatment
Treatment regime in comparison group: allopurinol 300 mg/m²/day or 10 mg/kg/day
divided every 8 hours for 5 to 7 days
Cointerventions: hydration 3 L/m²/day, iv sodium bicarbonate 20 to 40 mmol/L to
maintain urine pH 6.5 to 7
Outcomes • All-cause mortality
• Mortality due to tumour lysis syndrome
• Incidence of renal failure requiring renal replacement therapy
• Serial uric acid levels
• Frequency of adverse effects
Notes Duration of follow up: 12 days
Number of dropouts (intervention/comparison): 0/0
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because the treatment group had
more participants with lymphoma, higher uric acid level, lower LDH level, lower serum
creatinine, and phosphorus
Whether outcomes were clearly defined: yes
The report of adverse events included additional 24 participants who had received ras-
buricase in other centres
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
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Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All outcomes
High risk Serum uric acid data at 24 to 288 hours
post-treatment were missing in 6 to 12 par-
ticipants (43% to 86%)
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because the treatment group had
more participants with lymphoma, higher
uric acid level, lower LDH level, lower
serum creatinine, and phosphorus. Poten-
tial confounders were not adjusted. Use of
historical control may bias the results in
favour of the newer treatment because of
improvement in supportive care
Sánchez Tatay 2010
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants with haematological malignancies with tumour
lysis syndrome or at risk of tumour lysis syndrome, with at least 1 of the following
criteria: WBC > 50,000/uL or lactate dehydrogenase > 500 U/L; uric acid level ≥8
mg/dL or creatinine > 2 mg/dL; history of tumour lysis syndrome in previous cycles of
chemotherapy
Exclusion criteria: participants with history of hypersensitivity to rasburicase or allopuri-
nol, asthma, atopy, G6PD deficiency, or other metabolic causes of haemolytic anaemia
Number of participants (intervention/comparison): 16/16
Number of boys (intervention/comparison): not available
Age (intervention/comparison): not available
Underlying haematological malignancies (intervention/comparison): not available
Baseline uric acid (intervention/comparison): (median) 10.6 (SD 3.2)/11.3 (SD 5.8)
mg/dL
Baseline creatinine (intervention/comparison): (median) 0.93 (SD 0.81)/1.01 (SD 0.
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51) mg/dL
Baseline phosphate (intervention/comparison): (median) 6.28 (SD 2.29)/6.72 (SD 5.
02) mg/dL
Interventions Intervention (type of urate oxidase): rasburicase
Comparison (type of control): allopurinol
Treatment regime in intervention group: rasburicase 0.2 mg/kg ivi daily (duration of
treatment was not mentioned)
Treatment regime in comparison group: allopurinol 10 mg/kg/day divided every 8 hours
(duration of treatment was not mentioned)
Cointerventions: not mentioned
Outcomes • All-cause mortality
• Mortality due to tumour lysis syndrome
• Incidence of renal failure requiring renal replacement therapy
• Serial uric acid levels
• Frequency of adverse effects
Notes Duration of follow up: 4 days
Number of dropouts (intervention/comparison): 0/0
Potential confounders were not described or adjusted
Comparability of the treatment groups at baseline was uncertain because some important
baseline characteristics of comparison groups were not available
Whether outcomes were clearly defined: yes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All outcomes
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
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Other bias High risk Comparability of the treatment groups at
baseline was uncertain because some im-
portant baseline characteristics of compar-
ison groups were not available. Potential
confounders were not adjusted. Use of his-
torical controlmay bias the results in favour
of the newer treatment because of improve-
ment in supportive care
Wössmann 2003
Methods Design: CCT
Stratification factor: not applicable
Participants Inclusion criteria: paediatric participants ≤ 18 years with B-ALL or stage III and IV
B-NHL and LDH ≥ 500 U/L treated in the trials NHL-BFM 90 and 95, during the
period November 1997 to December 2001 (intervention group) or April 1990 toMarch
1996 (comparison group)
Exclusion criteria: nil
Number of participants (intervention/comparison): 130/218
Number of boys (intervention/comparison): N/A
Age (intervention/comparison): N/A
Underlying haematological malignancies: B-ALL 53/78; B-NHL 77/140
Baseline elevated LDH > 1000 U/L (intervention/comparison): 49.6%/47.2%
Interventions Intervention (type of urate oxidase): Uricozyme
Comparison (type of control): allopurinol and alkalinisation
Treatment regime in intervention group: Uricozyme 3 x 50 U/kg/day for 3 to 4 days
Treatment regime in comparison group: allopurinol 10 mg/kg/day + alkalinisation to
maintain urine pH 7
Cointerventions: hydration 3 to 4.5 L/m²/day
Outcomes • Incidence of clinical tumour lysis syndrome
• All-cause mortality
• Incidence of renal failure requiring renal replacement therapy
Notes Duration of follow up not reported
Number of dropouts (intervention/comparison): 0/0
Potential confounders were not described or adjusted
The 2 groups may not be comparable at baseline because the treatment group had fewer
participants who were critically ill or had complications after initial surgery
Whether outcomes were clearly defined: yes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk This was not a randomised controlled trial
Allocation concealment (selection bias) High risk This was not a randomised controlled trial,
and no allocation concealment was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not used
Incomplete outcome data (attrition bias)
All outcomes
Low risk The outcome data were complete for the
groups of participants analysed
Selective reporting (reporting bias) Unclear risk The study protocol was not available, and
it was unclear whether there was selective
reporting of outcomes
Other bias High risk The 2 groups may not be comparable at
baseline because the treatment group had
fewer participants who were critically ill or
had complications after initial surgery. Po-
tential confounders were not adjusted. Use
of historical control may bias the results in
favour of the newer treatment because of
improvement in supportive care
ALL:acutelymphoblasticleukaemia.
ALT :alanineaminotransf erase.
B−NHL:Bcellnon−Hodgkinlymphoma.
BUN :bloodureanitrogen.
CCT :controlledclinicaltrial.
ECOG:EasternCooperativeOncologyGroup.
G6PD:glucose−6−phosphatedehydrogenasedef iciency.
HBsAg:hepatitisBvirussurf aceantigen.
HCV :hepatitisCvirus.
iv:intravenous.
ivi:intravenousinf usion.
LDH :lactatedehydrogenase.
N/A:informationnotavailable.
NHL:non−Hodgkinlymphoma.
Po:takenorally.
RCT :randomisedcontrolledtrial.
SD:standarddeviation.
WBC:whitebloodcell(count).
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UKCCSG:UnitedKingdomChildren′sCancerStudyGroup.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cortes 2010 This was an RCT recruiting adult participants only and no paediatric participants
Ishizawa 2009 This was an RCT recruiting adult participants only and no paediatric participants
Vadhan-Raj 2012 This was an RCT recruiting adult participants only and no paediatric participants
RCT :randomisedcontrolledtrial.
Characteristics of ongoing studies [ordered by study ID]
NCT00199043
Trial name or title Randomised phase III trial of effectivity and safety of rasburicase compared with allopurinol for treatment of
hyperuricemia in patients with acute lymphoblastic leukemia or high-grade NHL with high risk of tumour
lysis syndrome (> 15 yrs)
Methods RCT
Participants Participants aged above 15 years, participating in the GMALL B-ALL/NHL-Study 2002; the GMALL-Study
07/2003; or the GMALL-Study Elderly 1/2003 that fulfil the following criteria: bulky disease (> 7.5 cm)
, high LDH (> 2 times the upper limit of normal), uric acid > 8 mg/dl (> 475 µmol/L) at diagnosis, and
leukocytes > 30000/µL
Interventions Arm 1: allopurinol
Arm 2: rasburicase
Outcomes Primary outcomes: renal function, uric acid, electrolytes, adverse events, mortality in pre-phase and the 2
following cycles of chemotherapy, time and dose compliance of chemotherapy
Secondary outcomes: response rate, incidence of tumour lysis syndrome
Starting date May 2003
Contact information Dieter Hoelzer, University Hospital, Medical Dept. II, Frankfurt, Germany, 60590
Notes Study completed. Results not available yet. Not all participants are eligible for this review (for example, elderly
participants may be included in this study)
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Trial name or title A randomized phase 2 study to evaluate the efficacy of rasburicase in patients at risk for TLS during two
cycles of chemotherapy
Methods RCT
Participants Participants that are high risk for TLS or potential/intermediate risk for TLS as described below: (a) High
risk: Hyperuricaemia of malignancy (uric acid levels > 7.5 mg/dL); or diagnosis of very aggressive lymphoma/
leukaemia based on Revised European-American Lymphoma (REAL) classification; acute myeloid leukaemia,
CML in blast crisis; high-grade myelodysplastic syndrome only if they have > 10% bone marrow blast
involvement and given aggressive treatment similar to acute myeloid leukaemia. (B) Potential risk: Diagnosis
of aggressive lymphoma/leukaemia based on REAL classification, plus 1 or more of the following criteria:
lactate dehydrogenase >/= 2 times the upper limit of normal; stage III to IV disease; stage I to II disease with
at least 1 lymph node/tumour > 5 cm in diameter. For participants with potential/intermediate risk for TLS,
only those planned to receive alternating regimens (or non-standard regimens) in 2 cycles (example; R-Hyper-
CVAD alternating with MTX/ARA-C) will be eligible
Interventions Arm A: Cycle 2 chemotherapy, rasburicase 0.15 mg/kg IV day 1, additional dose on days 2 to 5 at physician’s
discretion
Arm B: Cycle 2 chemotherapy, allopurinol 300 mg/day IV days 1 to 5 + rasburicase 0.15 mg/kg IV day 1 if
uric acid blood levels dictate single dose or more
Outcomes Primary outcome: Incidence of laboratory tumour lysis syndrome during cycle 2 (as defined by the Cairo-
Bishop criteria)
Starting date May 2011
Contact information Saroj Vadhan-Raj, UT MD Anderson Cancer Center, Houston, Texas, United States, 77030
Telephone: +1 713 792 7966
Notes Ongoing study recruiting participants. Not all participants are eligible for this review (for example, elderly
participants may be included in this study)
CML:chronicmyelogenousleukaemia.
R−Hyper−CV AD:chemotherapyregimenconsistingof rituximab,cyclophosphamide,vincristine,adriamycin,dexamethasone.
LDH :lactatedehydrogenase.
MT X/ARA−C:methotrexateandcytarabine.
NHL:non−Hodgkinlymphoma.
RCT :randomisedcontrolledtrial.
T LS:tumourlysissyndrome.
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D A T A A N D A N A L Y S E S
Comparison 1. Urate oxidase compared with allopurinol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of clinical tumour lysis
syndrome
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 CCT 1 348 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.44, 1.33]
2 Incidence of clinical tumour lysis
syndrome in B-ALL subgroup
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 CCT 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.18, 1.18]
3 All-cause mortality 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 CCT 3 406 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.42]
4 Mortality due to tumour lysis
syndrome
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 CCT 3 396 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.89]
5 Renal failure requiring renal
replacement therapy
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 CCT 5 992 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.08, 0.89]
6 Renal failure requiring renal
replacement therapy in B-ALL
subgroup
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 CCT 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.06, 1.05]
7 AUC of serum uric acid level at
4 days
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 RCT 1 52 Mean Difference (IV, Fixed, 95% CI) -201.0 [-258.05, -
143.95]
8 AUC of serum uric acid level at 4
days in leukaemia participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 RCT 1 39 Mean Difference (IV, Fixed, 95% CI) -220.0 [-286.67, -
153.33]
9 AUC of serum uric acid level at 4
days in lymphoma participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 RCT 1 13 Mean Difference (IV, Fixed, 95% CI) -132.0 [-185.47, -
78.53]
10 AUC of serum uric acid level
at 4 days in hyperuricemic
participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 RCT 1 19 Mean Difference (IV, Fixed, 95% CI) -278.0 [-373.69, -
182.31]
11 AUC of serum uric acid level
at 4 days in normouricemic
participants
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 RCT 1 33 Mean Difference (IV, Fixed, 95% CI) -240.0 [-340.95, -
139.05]
12 Serum uric acid level at 1 day 3 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 CCT 3 298 Mean Difference (IV, Random, 95% CI) -3.00 [-7.61, 1.60]
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13 Serum uric acid level at 2 days 3 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 CCT 3 294 Mean Difference (IV, Random, 95% CI) -3.80 [-7.37, -0.24]
14 Serum uric acid level at 3 days 2 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 CCT 2 47 Mean Difference (IV, Random, 95% CI) -3.13 [-6.12, -0.14]
15 Serum uric acid level at 4 days 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 CCT 2 45 Mean Difference (IV, Fixed, 95% CI) -4.6 [-6.39, -2.81]
16 Serum uric acid level at 5 days 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 CCT 1 14 Mean Difference (IV, Fixed, 95% CI) -1.02 [-2.24, 0.20]
17 Serum uric acid level at 7 days 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 CCT 1 16 Mean Difference (IV, Fixed, 95% CI) -1.74 [-3.01, -0.47]
18 Serum uric acid level at 12 days 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 CCT 1 20 Mean Difference (IV, Fixed, 95% CI) -0.80 [-2.51, 0.91]
19 Frequency of adverse events 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 CCT 3 345 Risk Ratio (M-H, Fixed, 95% CI) 9.10 [1.29, 64.00]
Comparison 2. High-dose urate oxidase compared with low-dose urate oxidase
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Normalisation of serum uric acid 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 RCT 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.89, 1.28]
2 Percentage reduction in serum
uric acid level at 4 hours
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 RCT 1 29 Mean Difference (IV, Fixed, 95% CI) 8.10 [-0.99, 17.19]
3 Frequency of adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 RCT 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.11, 2.33]
Analysis 1.1. Comparison 1 Urate oxidase compared with allopurinol, Outcome 1 Incidence of clinical
tumour lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 1 Incidence of clinical tumour lysis syndrome
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wo¨ssmann 2003 16/130 35/218 100.0 % 0.77 [ 0.44, 1.33 ]
Subtotal (95% CI) 130 218 100.0 % 0.77 [ 0.44, 1.33 ]
Total events: 16 (Urate oxidase), 35 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Urate oxidase compared with allopurinol, Outcome 2 Incidence of clinical
tumour lysis syndrome in B-ALL subgroup.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 2 Incidence of clinical tumour lysis syndrome in B-ALL subgroup
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wo¨ssmann 2003 5/53 16/78 100.0 % 0.46 [ 0.18, 1.18 ]
Subtotal (95% CI) 53 78 100.0 % 0.46 [ 0.18, 1.18 ]
Total events: 5 (Urate oxidase), 16 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.3. Comparison 1 Urate oxidase compared with allopurinol, Outcome 3 All-cause mortality.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 3 All-cause mortality
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
R nyi 2007 0/12 0/14 Not estimable
S nchez Tatay 2010 0/16 0/16 Not estimable
Wo¨ssmann 2003 0/130 4/218 100.0 % 0.19 [ 0.01, 3.42 ]
Subtotal (95% CI) 158 248 100.0 % 0.19 [ 0.01, 3.42 ]
Total events: 0 (Urate oxidase), 4 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 1.4. Comparison 1 Urate oxidase compared with allopurinol, Outcome 4 Mortality due to tumour
lysis syndrome.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 4 Mortality due to tumour lysis syndrome
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Patte 2002 0/152 11/186 100.0 % 0.05 [ 0.00, 0.89 ]
R nyi 2007 0/12 0/14 Not estimable
S nchez Tatay 2010 0/16 0/16 Not estimable
Subtotal (95% CI) 180 216 100.0 % 0.05 [ 0.00, 0.89 ]
Total events: 0 (Urate oxidase), 11 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.042)
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Analysis 1.5. Comparison 1 Urate oxidase compared with allopurinol, Outcome 5 Renal failure requiring
renal replacement therapy.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 5 Renal failure requiring renal replacement therapy
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CCT
Patte 2002 4/152 38/186 35.6 % 0.13 [ 0.05, 0.35 ]
Pui 1997 0/119 0/129 Not estimable
R nyi 2007 0/12 1/14 11.6 % 0.38 [ 0.02, 8.65 ]
S nchez Tatay 2010 0/16 6/16 13.6 % 0.08 [ 0.00, 1.26 ]
Wo¨ssmann 2003 8/130 20/218 39.2 % 0.67 [ 0.30, 1.48 ]
Subtotal (95% CI) 429 563 100.0 % 0.26 [ 0.08, 0.89 ]
Total events: 12 (Urate oxidase), 65 (Allopurinol)
Heterogeneity: Tau2 = 0.83; Chi2 = 7.96, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 2.15 (P = 0.031)
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Analysis 1.6. Comparison 1 Urate oxidase compared with allopurinol, Outcome 6 Renal failure requiring
renal replacement therapy in B-ALL subgroup.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 6 Renal failure requiring renal replacement therapy in B-ALL subgroup
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Wo¨ssmann 2003 2/53 12/78 100.0 % 0.25 [ 0.06, 1.05 ]
Subtotal (95% CI) 53 78 100.0 % 0.25 [ 0.06, 1.05 ]
Total events: 2 (Urate oxidase), 12 (Allopurinol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
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Analysis 1.7. Comparison 1 Urate oxidase compared with allopurinol, Outcome 7 AUC of serum uric acid
level at 4 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 7 AUC of serum uric acid level at 4 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 27 128 (70) 25 329 (129) 100.0 % -201.00 [ -258.05, -143.95 ]
Subtotal (95% CI) 27 25 100.0 % -201.00 [ -258.05, -143.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.91 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Urate oxidase compared with allopurinol, Outcome 8 AUC of serum uric acid
level at 4 days in leukaemia participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 8 AUC of serum uric acid level at 4 days in leukaemia participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 20 141 (75) 19 361 (129) 100.0 % -220.00 [ -286.67, -153.33 ]
Subtotal (95% CI) 20 19 100.0 % -220.00 [ -286.67, -153.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Urate oxidase compared with allopurinol, Outcome 9 AUC of serum uric acid
level at 4 days in lymphoma participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 9 AUC of serum uric acid level at 4 days in lymphoma participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 7 92 (41) 6 224 (55) 100.0 % -132.00 [ -185.47, -78.53 ]
Subtotal (95% CI) 7 6 100.0 % -132.00 [ -185.47, -78.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Urate oxidase compared with allopurinol, Outcome 10 AUC of serum uric
acid level at 4 days in hyperuricemic participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 10 AUC of serum uric acid level at 4 days in hyperuricemic participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 10 162 (87) 9 440 (121) 100.0 % -278.00 [ -373.69, -182.31 ]
Subtotal (95% CI) 10 9 100.0 % -278.00 [ -373.69, -182.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.69 (P < 0.00001)
Test for subgroup differences: Not applicable
-500 -250 0 250 500
Favours urate oxidase Favours allopurinol
44Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.11. Comparison 1 Urate oxidase compared with allopurinol, Outcome 11 AUC of serum uric
acid level at 4 days in normouricemic participants.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 11 AUC of serum uric acid level at 4 days in normouricemic participants
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Goldman 2001 17 108 (51) 16 348 (200) 100.0 % -240.00 [ -340.95, -139.05 ]
Subtotal (95% CI) 17 16 100.0 % -240.00 [ -340.95, -139.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Urate oxidase compared with allopurinol, Outcome 12 Serum uric acid level
at 1 day.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 12 Serum uric acid level at 1 day
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CCT
Pui 1997 119 1 (3.81) 129 3.4 (5.64) 36.1 % -2.40 [ -3.59, -1.21 ]
R nyi 2007 12 6.17 (3.38) 6 4.12 (4.54) 28.6 % 2.05 [ -2.06, 6.16 ]
S nchez Tatay 2010 16 0.5 (1.7) 16 8.2 (2.8) 35.4 % -7.70 [ -9.31, -6.09 ]
Subtotal (95% CI) 147 151 100.0 % -3.00 [ -7.61, 1.60 ]
Heterogeneity: Tau2 = 14.92; Chi2 = 35.69, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Urate oxidase compared with allopurinol, Outcome 13 Serum uric acid level
at 2 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 13 Serum uric acid level at 2 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CCT
Pui 1997 119 1.1 (3.57) 129 2.8 (4.73) 41.3 % -1.70 [ -2.74, -0.66 ]
R nyi 2007 12 0.98 (1.38) 2 4.63 (3.91) 21.3 % -3.65 [ -9.12, 1.82 ]
S nchez Tatay 2010 16 0.5 (1.5) 16 6.7 (3.9) 37.5 % -6.20 [ -8.25, -4.15 ]
Subtotal (95% CI) 147 147 100.0 % -3.80 [ -7.37, -0.24 ]
Heterogeneity: Tau2 = 7.74; Chi2 = 14.89, df = 2 (P = 0.00058); I2 =87%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Urate oxidase compared with allopurinol, Outcome 14 Serum uric acid level
at 3 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 14 Serum uric acid level at 3 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CCT
R nyi 2007 12 0.67 (0.64) 3 2.32 (1.03) 51.5 % -1.65 [ -2.87, -0.43 ]
S nchez Tatay 2010 16 0.4 (0.7) 16 5.1 (3.2) 48.5 % -4.70 [ -6.31, -3.09 ]
Subtotal (95% CI) 28 19 100.0 % -3.13 [ -6.12, -0.14 ]
Heterogeneity: Tau2 = 4.12; Chi2 = 8.79, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Urate oxidase compared with allopurinol, Outcome 15 Serum uric acid level
at 4 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 15 Serum uric acid level at 4 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 0.3 (0.3) 1 1.43 (0) Not estimable
S nchez Tatay 2010 16 0.2 (0.6) 16 4.8 (3.6) 100.0 % -4.60 [ -6.39, -2.81 ]
Subtotal (95% CI) 28 17 100.0 % -4.60 [ -6.39, -2.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Urate oxidase compared with allopurinol, Outcome 16 Serum uric acid level
at 5 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 16 Serum uric acid level at 5 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 0.44 (0.48) 2 1.46 (0.86) 100.0 % -1.02 [ -2.24, 0.20 ]
Subtotal (95% CI) 12 2 100.0 % -1.02 [ -2.24, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Urate oxidase compared with allopurinol, Outcome 17 Serum uric acid level
at 7 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 17 Serum uric acid level at 7 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 1.43 (1.06) 4 3.17 (1.14) 100.0 % -1.74 [ -3.01, -0.47 ]
Subtotal (95% CI) 12 4 100.0 % -1.74 [ -3.01, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Urate oxidase compared with allopurinol, Outcome 18 Serum uric acid level
at 12 days.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 18 Serum uric acid level at 12 days
Study or subgroup Urate oxidase Allopurinol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CCT
R nyi 2007 12 2.34 (1.49) 8 3.14 (2.14) 100.0 % -0.80 [ -2.51, 0.91 ]
Subtotal (95% CI) 12 8 100.0 % -0.80 [ -2.51, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Urate oxidase compared with allopurinol, Outcome 19 Frequency of adverse
events.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 1 Urate oxidase compared with allopurinol
Outcome: 19 Frequency of adverse events
Study or subgroup Urate oxidase Allopurinol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CCT
Pui 1997 7/134 0/129 41.7 % 14.44 [ 0.83, 250.35 ]
R nyi 2007 6/36 0/14 58.3 % 5.27 [ 0.32, 87.82 ]
S nchez Tatay 2010 0/16 0/16 Not estimable
Subtotal (95% CI) 186 159 100.0 % 9.10 [ 1.29, 64.00 ]
Total events: 13 (Urate oxidase), 0 (Allopurinol)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 1
Normalisation of serum uric acid.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 2 High-dose urate oxidase compared with low-dose urate oxidase
Outcome: 1 Normalisation of serum uric acid
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 14/14 14/15 100.0 % 1.07 [ 0.89, 1.28 ]
Subtotal (95% CI) 14 15 100.0 % 1.07 [ 0.89, 1.28 ]
Total events: 14 (High dose), 14 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 2
Percentage reduction in serum uric acid level at 4 hours.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 2 High-dose urate oxidase compared with low-dose urate oxidase
Outcome: 2 Percentage reduction in serum uric acid level at 4 hours
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Kikuchi 2009 14 92.9 (7.9) 15 84.8 (16) 100.0 % 8.10 [ -0.99, 17.19 ]
Subtotal (95% CI) 14 15 100.0 % 8.10 [ -0.99, 17.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 High-dose urate oxidase compared with low-dose urate oxidase, Outcome 3
Frequency of adverse events.
Review: Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Comparison: 2 High-dose urate oxidase compared with low-dose urate oxidase
Outcome: 3 Frequency of adverse events
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 RCT
Kikuchi 2009 2/15 4/15 100.0 % 0.50 [ 0.11, 2.33 ]
Subtotal (95% CI) 15 15 100.0 % 0.50 [ 0.11, 2.33 ]
Total events: 2 (High dose), 4 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL)
The following text words were used:
urate oxidase OR uricase OR uricas* rasburicase OR rasburicas* OR elitek OR fasturtec OR fasturt* OR uox
The search was performed in title, abstract or keywords
[*=zero or more characters]
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Appendix 2. Search strategy for PubMed
1. For Urate oxidase the following MeSH headings and text words were used:
urate oxidase OR uricase OR uricas* OR oxidase, urate OR EC 1.7.3.3. OR rasburicase OR rasburicas* OR elitek OR fasturtec OR
fasturt* OR uox
2. For Children the following MeSH headings and text words were used:
infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR
schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen*
OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR
puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary
school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery
OR infant, newborn
3. For Cochrane RCTs/CCTs the following MeSH headings and text words were used in the original version of the review:
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh]
OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw])
OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo*
[tw] OR random* [tw] OR research design [mh:NoExp]OR comparative study [mh]OR evaluation studies [mh]OR follow-up studies
[mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans
[mh]))
For the update in 2013 the following search strategy for identifying RCTs and CCTs was used:
((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh])
OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) AND (humans[mh])
Final search: 1 AND 2 AND 3
[CCT = controlled clinical trial; RCT = randomized controlled trial; mh = Medical Subject Heading (MeSH) term; pt =publication
type; tw: text word]
Appendix 3. Search strategy for Embase (OVID)
1. For Urate oxidase the following Emtree terms and text words were used:
1. urate oxidase.mp. or Urate Oxidase/
2. (rasburicase or uox).mp.
3. (uricase or elitek).mp.
4. (9002-12-4 or 352311-12-7).rn. or EC 1733.mp.
5. (uricas$ or rasburicas$ or fasturtec or fasturt$).mp.
6. or/1-5
2. For Children the following Emtree terms and text words were used:
1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/
2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/
3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/
4. or/1-3
5. (infant$ or (newborn$ or new born$) or (baby or baby$ or babies) or neonate$).mp.
6. (child$ or (school child$ or schoolchild$) or (school age$ or schoolage$) or (pre school$ or preschool$)).mp.
7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.
8. (minors$ or (under ag$ or underage$) or juvenil$ or youth$).mp.
9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.
10. (pediatric$ or paediatric$ or peadiatric$).mp.
11. (school or schools or (high school$ or highschool$) or primary school$ or nursery school$ or elementary school or secondary
school$ or kindergar$).mp.
12. or/5-11
13. 4 or 12
3. For RCTs/CCTs the following Emtree terms and text words were used in the original version of the review:
1. Clinical Trial/
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2. Controlled Study/
3. Randomized Controlled Trial/
4. Double Blind Procedure/
5. Single Blind Procedure/
6. Comparative Study/
7. RANDOMIZATION/
8. Prospective Study/
9. PLACEBO/
10. Phase 2 Clinical Trial/
11. phase 3 clinical study.mp.
12. phase 4 clinical study.mp.
13. Phase 3 Clinical Trial/
14. Phase 4 Clinical Trial/
15. or/1-14
16. allocat$.mp.
17. blind$.mp.
18. control$.mp.
19. placebo$.mp.
20. prospectiv$.mp.
21. random$.mp.
22. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.
23. (versus or vs).mp.
24. (randomized controlled trial$ or randomised controlled trial$).mp.
25. controlled clinical trial$.mp.
26. clinical trial$.mp.
27. or/16-27
28. Human/
29. Nonhuman/
30. ANIMAL/
31. Animal Experiment/
32. or/29-31
33. 32 not 28
34. (15 or 27) not 33
For the update in 2013 the following search strategy for identifying RCTs and CCTs was used:
1. Randomized Controlled Trial/
2. Controlled Clinical Trial/
3. randomized.ti,ab.
4. placebo.ti,ab.
5. randomly.ti,ab.
6. trial.ti,ab.
7. groups.ti,ab.
8. drug therapy.sh.
9. or/1-8
10. Human/
11. 9 and 10
Final search: 1 and 2 and 3 (Urate oxidase AND Children AND RCT)
[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name;
sh = subject heading; ti,ab = title, abstract; / = Emtree term; $ = zero or more characters; rn = registry number; RCT = randomized
controlled trial; CCT = controlled clinical trial]
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Appendix 4. Search strategy for CINAHL
1. For Urate oxidase the following text words were used:
urate oxidase OR rasburicase OR uox OR uricase OR elitek OR fasfurtec
2. For Children the following text words were used:
neonate OR infant OR newborn OR baby OR child OR preschool OR school OR adolescent OR juvenile OR boy OR girl OR
puberty OR pediatric OR kindergarten OR nursery OR kid OR minors
3. For RCTs/CCTs the following text words were used:
trial OR control OR placebo OR random OR prospective study OR comparative study
In the final search the three searches were combined: 1 AND 2 AND 3
WH A T ’ S N E W
Last assessed as up-to-date: 26 February 2013.
Date Event Description
1 August 2013 New citation required and conclusions have changed Two new studies were found and included in the up-
date. Conclusions regarding efficacy outcomes did not
change, whereas for adverse effects they did
26 February 2013 New search has been performed The search for eligible studies was updated to February
2013
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 6, 2010
Date Event Description
17 June 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Cheuk DKL: protocol development, searching for trials, quality assessment of trials, data extraction, data input, data analyses, devel-
opment of final review, corresponding author.
Chiang AKS: protocol development, quality assessment of trials, data extraction, data input, data analyses, development of final review.
Chan GCF: protocol development, development of final review.
Ha SY: protocol development, development of final review.
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The Library of The University of Hong Kong provided support in retrieving full-texts of studies.
External sources
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Weused themean difference for continuous outcomes instead of the weightedmean difference.We updated the ’Risk of bias’ assessment
according to the latest version of theCochrane Handbook for Systematic Reviews of Interventions (version 5.1.0).We still reported outcomes
with less than 70% of participants’ data, but we considered them to be prone to bias. We did not calculate RR if there was only one
study available for a particular outcome and there was no event in one of the groups; we used the Fisher’s exact test (performed using
SPSS 19) to determine the P value in such situations. In this update, we changed the unit of uric acid measurements to mg/dL, instead
of micromol/L in the original review, as mg/dL appeared to be more widely used.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Allopurinol [therapeutic use]; Antimetabolites [therapeutic use]; Area Under Curve; Controlled Clinical Trials as Topic; Neoplasms
[∗drug therapy]; Randomized Controlled Trials as Topic; Renal Insufficiency [prevention& control]; Tumor Lysis Syndrome [mortality;
∗prevention & control]; Urate Oxidase [adverse effects; ∗therapeutic use]; Uric Acid [blood]
MeSH check words
Adolescent; Child; Humans
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